Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1992 Nov;66(5):977-80.
doi: 10.1038/bjc.1992.395.

Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum

Affiliations
Free PMC article
Comparative Study

Comparison of plasma prolactin and CEA in monitoring patients with adenocarcinoma of colon and rectum

J M Bhatavdekar et al. Br J Cancer. 1992 Nov.
Free PMC article

Abstract

Plasma prolactin (PRL) and carcinoembryonic antigen (CEA) were measured by radioimmunoassay in 74 patients with adenocarcinoma of colon and rectum. The markers were correlated with disease stage, histological grade and progression/remission of disease. The circulating preoperative median PRL and CEA levels were significantly higher in colorectal cancer patients than in their respective controls. PRL was elevated in all Dukes stages and in all histological grades of the tumour whereas the rise in CEA was more pronounced in Dukes D. Out of 74 patients, 29% (21/74) developed recurrent disease and 31% (23/74) responded to the treatment. With regard to monitoring recurrence(s), the predictive value of PRL was 94% which was significantly greater than that of CEA which was only 62%. In patients who developed liver metastases PRL remained elevated whereas CEA showed more than 100-fold increase. Therefore, we feel that CEA is a better marker for monitoring patients who developed liver metastases. From our results, we suggest that PRL can be used as a better overall marker for detecting recurrence(s) in patients with colorectal adenocarcinoma.

PubMed Disclaimer

References

    1. J Natl Cancer Inst. 1978 Aug;61(2):315-8 - PubMed
    1. JAMA. 1978 Mar 13;239(11):1065-6 - PubMed
    1. Am J Surg. 1990 Jun;159(6):593-6 - PubMed
    1. Cancer. 1990 May 1;65(9):2028-32 - PubMed
    1. Br J Cancer. 1958 Sep;12(3):309-20 - PubMed

Publication types

MeSH terms